Back to search
FDAFDA · Food and drugs·Recall number D-0170-2021

Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA 02210, NDC 59922-631-01

Published December 30, 2020 · Recall initiated: December 9, 2020

Summary

FDA records drug Class II recall D-0170-2021, published December 30, 2020 and initiated December 9, 2020. Recalling firm: Akebia Therapeutics dba Keryx Biopharmaceutials, Inc; Status: Terminated; Reported quantity: 2,170 bottles; Lot: Lot Number: 9062, exp. date Feb 2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations

What to do

Voluntary: Firm initiated · Letter

Get an email if AURYXIA has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
AURYXIA
Manufacturer
Akebia Therapeutics dba Keryx Biopharmaceutials, Inc
Distributor
The product was distributed by two major distributors who further distributed the product nationwide and one specialty pharmacy.
Lot
Lot Number: 9062, exp. date Feb 2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Auryxia (ferric citrate) tablets, 210 mg, 200-count bottles, Rx only, Manufactured for and distributed by: KERYX BIOPHARMACEUTICALS, INC., One Marina Park Drive, 12th Floor, Boston, MA 02210, NDC 59922-631-01 recalled?

Yes. FDA published recall D-0170-2021 on December 30, 2020. Reported hazard: CGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: AURYXIA.